Handelsbanken Fonder AB Has $6.27 Million Position in Roivant Sciences Ltd. $ROIV

Key Points

• Handelsbanken Fonder AB increased its Roivant Sciences stake by 51.4% in the second quarter, owning 177,209 shares valued at approximately $6.27 million.
• Institutional investors own 64.76% of Roivant’s stock, while insiders sold roughly 2.06 million shares worth $69.6 million over the past three months.
• Analysts maintain a generally positive outlook, with the stock receiving a consensus “Moderate Buy” rating and an average price target of $35.14; shares recently opened at $36.20.

Handelsbanken Fonder AB lifted its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 51.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 177,209 shares of the company's stock after acquiring an additional 60,200 shares during the period. Handelsbanken Fonder AB's holdings in Roivant Sciences were worth $6,271,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Assenagon Asset Management S.A. boosted its holdings in shares of Roivant Sciences by 18.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company's stock valued at $295,965,000 after purchasing an additional 1,286,464 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Roivant Sciences by 17.4% during the 2nd quarter. GAMMA Investing LLC now owns 14,637 shares of the company's stock worth $518,000 after buying an additional 2,172 shares during the last quarter. Versant Capital Management Inc boosted its stake in Roivant Sciences by 13.9% in the second quarter. Versant Capital Management Inc now owns 3,995 shares of the company's stock valued at $141,000 after buying an additional 487 shares in the last quarter. Pacer Advisors Inc. grew its position in Roivant Sciences by 37.1% in the first quarter. Pacer Advisors Inc. now owns 96,303 shares of the company's stock valued at $2,668,000 after acquiring an additional 26,044 shares during the last quarter. Finally, Empowered Funds LLC grew its position in Roivant Sciences by 1,468.5% in the first quarter. Empowered Funds LLC now owns 285,915 shares of the company's stock valued at $7,920,000 after acquiring an additional 267,686 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ROIV shares. Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a research note on Thursday, May 21st. Weiss Ratings cut Roivant Sciences from a "sell (d)" rating to a "sell (d-)" rating in a research note on Friday, May 22nd. TD Cowen restated a "buy" rating on shares of Roivant Sciences in a research report on Thursday, August 6th. Guggenheim upped their target price on Roivant Sciences from $36.00 to $42.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Finally, Citigroup lifted their price target on Roivant Sciences from $42.00 to $46.00 and gave the company a "buy" rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $35.14.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the company's stock in a transaction on Monday, July 27th. The shares were sold at an average price of $34.95, for a total transaction of $6,990,000.00. Following the sale, the chief executive officer owned 1,613,063 shares of the company's stock, valued at approximately $56,376,551.85. This represents a 11.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Daniel Allen Gold sold 12,380 shares of the stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.28, for a total value of $436,766.40. Following the sale, the director owned 13,689,166 shares of the company's stock, valued at approximately $482,953,776.48. The trade was a 0.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 2,055,913 shares of company stock worth $69,639,633 over the last three months. 8.80% of the stock is owned by company insiders.

Roivant Sciences Stock Down 0.2%

Shares of NASDAQ:ROIV opened at $36.20 on Friday. The firm has a market cap of $26.04 billion, a P/E ratio of -68.30 and a beta of 1.12. Roivant Sciences Ltd. has a 12-month low of $11.54 and a 12-month high of $37.00. The business has a fifty day simple moving average of $33.84 and a 200 day simple moving average of $29.91.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source